PVLA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Palvella Therapeutics Inc (PVLA) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong Phase 3 SELVA trial results, consistent analyst upgrades with high price targets, and potential for FDA approval make it a compelling opportunity despite current short-term price fluctuations.
The technical indicators are bullish. The MACD is positive and contracting, suggesting upward momentum. The RSI is neutral at 71.502, and the moving averages (SMA_5 > SMA_20 > SMA_200) indicate a bullish trend. The stock is trading above key support levels, with resistance at R1: 145.687.
Phase 3 SELVA trial results for Qtorin rapamycin exceeded expectations, positioning the company for FDA approval and potential blockbuster status.
Analysts have consistently raised price targets, with a range of $209-$255, reflecting strong confidence in the company's prospects.
The recent $230 million upsized public offering strengthens the company's financial position to support development programs.
Short-term price weakness with a -3.66% pre-market change and -0.34% regular market change.
No significant hedge fund or insider trading activity, indicating neutral sentiment from key stakeholders.
In Q3 2025, the company reported a net income improvement of 62.79% YoY, though it remains negative at -$11.35 million. EPS dropped significantly by -73.86% YoY, but this is expected for a pre-revenue biotech company. Revenue and gross margin remain at 0, which is typical for companies in this stage of development.
Analysts are overwhelmingly positive, with multiple firms raising price targets to $209-$255 and maintaining Buy or Outperform ratings. Analysts highlight the SELVA trial's success and the high probability of FDA approval as key drivers for the stock's future growth.
